CBER/CDER Oncology Divisions Will Remain Separate, FDA Confirms

Maintaining separate oncology review teams for drugs and biologics will help to ensure a "smooth" transition in the reorganization of CBER and CDER, Office of New Drugs Deputy Director Sandra Kweder, MD, said Dec. 11